<?xml version="1.0" encoding="UTF-8"?>
<ref id="B150-molecules-26-00431">
 <label>150.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Stevenson</surname>
    <given-names>J.P.</given-names>
   </name>
   <name>
    <surname>DeMaria</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Reilly</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Purvis</surname>
    <given-names>J.D.</given-names>
   </name>
   <name>
    <surname>Graham</surname>
    <given-names>M.A.</given-names>
   </name>
   <name>
    <surname>Lockwood</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Drozd</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Oâ€™Dwyer</surname>
    <given-names>P.J.</given-names>
   </name>
  </person-group>
  <article-title>Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule</article-title>
  <source>Cancer Chemother. Pharmacol.</source>
  <year>1999</year>
  <volume>44</volume>
  <fpage>228</fpage>
  <lpage>234</lpage>
  <pub-id pub-id-type="doi">10.1007/s002800050971</pub-id>
  <pub-id pub-id-type="pmid">10453724</pub-id>
 </element-citation>
</ref>
